FDA Approves Nexavar For Liver Cancer Therapy

The US Food and Drug Administration (FDA) has approved Nexavar (sorafenib) tablets, a supplemental NDA (new drug application) for patients with liver cancer (unresectable hepatocellular carcinoma, or HCC). It is the first approved systemic drug therapy for liver cancer, as well as being the only medication therapy proven to significantly improve overall survival in liver cancer patients. Last month Nexavar was approved in Europe for HCC treatment. [click link for full article]

More: continued here

Filed under: Cancer on November 20th, 2007